CA3181793A1 - Imidazopyrimidines as modulators of il-17 - Google Patents
Imidazopyrimidines as modulators of il-17Info
- Publication number
- CA3181793A1 CA3181793A1 CA3181793A CA3181793A CA3181793A1 CA 3181793 A1 CA3181793 A1 CA 3181793A1 CA 3181793 A CA3181793 A CA 3181793A CA 3181793 A CA3181793 A CA 3181793A CA 3181793 A1 CA3181793 A1 CA 3181793A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- cycloalkyl
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017679P | 2020-04-30 | 2020-04-30 | |
| US63/017,679 | 2020-04-30 | ||
| PCT/IB2021/053517 WO2021220183A1 (en) | 2020-04-30 | 2021-04-28 | Imidazopyrimidines as modulators of il-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3181793A1 true CA3181793A1 (en) | 2021-11-04 |
Family
ID=75769661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3181793A Pending CA3181793A1 (en) | 2020-04-30 | 2021-04-28 | Imidazopyrimidines as modulators of il-17 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12559496B2 (enExample) |
| EP (1) | EP4143193B1 (enExample) |
| JP (1) | JP7661361B2 (enExample) |
| KR (1) | KR20230018387A (enExample) |
| CN (1) | CN115867348B (enExample) |
| AU (1) | AU2021262588A1 (enExample) |
| BR (1) | BR112022021957A2 (enExample) |
| CA (1) | CA3181793A1 (enExample) |
| ES (1) | ES3071556T3 (enExample) |
| IL (1) | IL297734A (enExample) |
| MX (1) | MX2022013650A (enExample) |
| WO (1) | WO2021220183A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201909190D0 (en) * | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2023111181A1 (en) | 2021-12-16 | 2023-06-22 | Leo Pharma A/S | Small molecule modulators of il-17 |
| EP4486737A1 (en) | 2022-03-04 | 2025-01-08 | LEO Pharma A/S | Small molecule modulators of il-17 |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| EP4688156A1 (en) * | 2023-03-28 | 2026-02-11 | Janssen Pharmaceutica NV | Lactam-containing imidazopyridazine il-17 inhibitor compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2809660B1 (en) * | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| GB201321736D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| ES2702126T3 (es) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| MA40759A (fr) * | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| US10152431B2 (en) | 2015-03-16 | 2018-12-11 | Honeywell International Inc. | System and method for remote set-up and adjustment of peripherals |
| KR102782807B1 (ko) * | 2015-11-18 | 2025-03-14 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
| GB201709456D0 (en) | 2017-06-14 | 2017-07-26 | Ucb Biopharma Sprl | Therapeutic agents |
| CN111601799B (zh) | 2018-01-15 | 2023-06-09 | Ucb生物制药有限责任公司 | 作为Il-17调节剂的稠合咪唑衍生物 |
| WO2019223718A1 (zh) | 2018-05-22 | 2019-11-28 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| US11993574B2 (en) | 2018-06-15 | 2024-05-28 | Reata Pharmaceuticals, Inc | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma |
| WO2020011731A1 (en) | 2018-07-12 | 2020-01-16 | UCB Biopharma SRL | Spirocyclic indane analogues as il-17 modulators |
| JP7664947B2 (ja) | 2020-04-30 | 2025-04-18 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｉｌ－１７の調節因子としてのイミダゾリダジン |
| KR20230017211A (ko) | 2020-04-30 | 2023-02-03 | 얀센 파마슈티카 엔.브이. | Il-17 경로의 조절인자를 식별하는 방법 |
| WO2021219784A1 (en) | 2020-04-30 | 2021-11-04 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
-
2021
- 2021-04-28 US US17/997,437 patent/US12559496B2/en active Active
- 2021-04-28 WO PCT/IB2021/053517 patent/WO2021220183A1/en not_active Ceased
- 2021-04-28 EP EP21723010.1A patent/EP4143193B1/en active Active
- 2021-04-28 AU AU2021262588A patent/AU2021262588A1/en not_active Abandoned
- 2021-04-28 CN CN202180047235.4A patent/CN115867348B/zh active Active
- 2021-04-28 MX MX2022013650A patent/MX2022013650A/es unknown
- 2021-04-28 BR BR112022021957A patent/BR112022021957A2/pt not_active Application Discontinuation
- 2021-04-28 CA CA3181793A patent/CA3181793A1/en active Pending
- 2021-04-28 KR KR1020227041944A patent/KR20230018387A/ko not_active Withdrawn
- 2021-04-28 JP JP2022566012A patent/JP7661361B2/ja active Active
- 2021-04-28 IL IL297734A patent/IL297734A/en unknown
- 2021-04-28 ES ES21723010T patent/ES3071556T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022021957A2 (pt) | 2023-01-17 |
| CN115867348B (zh) | 2025-05-06 |
| AU2021262588A1 (en) | 2023-01-19 |
| ES3071556T3 (en) | 2026-06-24 |
| JP2023523770A (ja) | 2023-06-07 |
| EP4143193C0 (en) | 2026-04-22 |
| CN115867348A (zh) | 2023-03-28 |
| WO2021220183A1 (en) | 2021-11-04 |
| US20230242537A1 (en) | 2023-08-03 |
| MX2022013650A (es) | 2023-02-01 |
| US12559496B2 (en) | 2026-02-24 |
| EP4143193B1 (en) | 2026-04-22 |
| JP7661361B2 (ja) | 2025-04-14 |
| IL297734A (en) | 2022-12-01 |
| KR20230018387A (ko) | 2023-02-07 |
| EP4143193A1 (en) | 2023-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12559496B2 (en) | Imidazopyrimidines as modulators of IL-17 | |
| JP7365059B2 (ja) | 縮合チオフェン化合物 | |
| RU2684324C1 (ru) | Бициклические конденсированные гетероарильные или арильные соединения в качестве модуляторов IRAK4 | |
| BR112021007861A2 (pt) | compostos heterocíclicos substituídos por amida | |
| JP2023524018A (ja) | Ｉｌ－１７の調節因子としてのイミダゾリダジン | |
| JP2022539538A (ja) | Ｉｌ－１７調節剤としての縮合イミダゾール誘導体 | |
| US10047092B2 (en) | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | |
| SG188883A1 (en) | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | |
| CA3233408A1 (en) | Imidazopyridazine il-17 inhibitor compounds | |
| US6710064B2 (en) | Hydantoin compounds useful as anti-inflammatory agents | |
| KR20240082371A (ko) | 이미다조피리다진 il-17 억제제 화합물 | |
| US20260098018A1 (en) | Bicyclic 1,4-diazepanones and therapeutic uses thereof | |
| KR20240115978A (ko) | Lpa 수용체 길항제 및 이의 용도 | |
| JP2015520217A (ja) | ２ｈ−イミダゾール−４−アミン化合物およびｂａｃｅ阻害物質としてのその使用 | |
| CA3233622A1 (en) | Benzimidazole and azabenzimidazole il-17 inhibitor compounds | |
| US20250188079A1 (en) | Inhibiting cyclic amp-responsive element-binding protein (creb) | |
| AU2017378316A1 (en) | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use | |
| AU2024271421A1 (en) | Thiazole derivative inhibitor, and preparation method therefor and use thereof | |
| AU2024244259A1 (en) | Kcc2 potentiators and uses thereof | |
| JP2023513121A (ja) | Ａｄａｍｔｓ阻害剤、その製造および医薬用途 | |
| WO2025202931A1 (en) | Imidazopyridazine il-17 inhibitor compounds | |
| WO2025202922A1 (en) | Imidazopyridazine il-17 inhibitor compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241227 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241227 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250425 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250425 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250425 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250702 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250702 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250702 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260303 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260303 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260309 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20260421 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260519 |